Drug Profile
PMA 101R
Alternative Names: PMA-101RLatest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Pharmedartis
- Class Anti-inflammatories; Antineoplastics; Skin disorder therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Atopic dermatitis; Inflammation; Psoriasis; Rheumatoid arthritis; Solid tumours
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Acute myeloid leukaemia in Germany (unspecified route)
- 06 Sep 2023 Discontinued - Preclinical for Atopic dermatitis in Germany (unspecified route)
- 06 Sep 2023 Discontinued - Preclinical for Inflammation in Germany (unspecified route)